Exclusive | Lindsay Clancy trial spotlights controversial antipsychotic — and some claim it ‘ruined’ their lives

The murder trial of Lindsay Clancy is bringing renewed scrutiny to the prescription of the antipsychotic drug Seroquel for off-label sleep treatment. Clancy was prescribed the medication by a nurse practitioner in the months leading up to the 2023 death of her three children. While the drug is FDA-approved for specific psychiatric conditions, its use for insomnia remains a polarizing practice among medical professionals.

Defense attorneys in the case argue that the cocktail of medications Clancy received contributed to her declining mental state and an eventual psychotic break. Testimony confirms she reported new intrusive thoughts, panic attacks, and suicidal ideation after starting the drug. Experts note that using such a potent medication for insomnia carries significant risks, including potential sleepwalking and severe withdrawal symptoms, which are difficult to manage in an outpatient setting.

Physicians who spoke on the matter point to a broader concern about modern psychiatric care. Some suggest that high patient loads lead providers to prescribe medication based on trial and error rather than precise diagnosis. This approach often results in patients being placed on powerful drugs without adequate monitoring or informed consent regarding the potential for nervous-system reactions like hallucinations or mania.

Past regulatory actions underscore these concerns, specifically a 2010 settlement involving manufacturer AstraZeneca over allegations of illegal off-label marketing for insomnia. While some patients report that the drug provides necessary stability when other options fail, others describe profound personal damage, including a persistent trance-like state and physical health changes.

As the court examines the role these medications played in the days before the tragedy, the case highlights the tension between clinical utility and patient safety. Medical professionals continue to debate the standard of care for prescribing antipsychotics when primary interventions for sleep disorders do not produce the desired results.